Discussion
SAD, residual neuromuscular blockade
Using modified Dixon’s up-and-down method, we found that the remimazolam bolus dose needed for successful I-gel insertion in 50% of adult patients was 0.280 ± 0.048 mg/kg when co-administered with Ce 3.0 ng/mL of remifentanil without NMBAs. Moreover, remimazolam bolus induction resulted in a mean LOC time (MOAA/S < 2) of 52.2 s. This study showed that remimazolam bolus can be used in combination with remifentanil for I-gel insertion with rapid induction when patients need to recover without the concern of residual neuromuscular blockade.Remifentanil is a short-acting μ-receptor agonist and, similar to remimazolam, it produces a fast onset and has the advantage of quick degradation by plasma or tissue esterase, showing high clearance and a short context-sensitive half-life [As mentioned previously, propofol has been extensively used for SAD insertion because it strongly inhibits airway reflex. Numerous SAD studies have found an appropriate dose of remifentanil co-administered with propofol to facilitate the device [When a new drug is developed, researchers continue to find efficient methods to improve safety, efficacy, onset, and recovery profiles, while minimizing side effects [Clinically, a BIS value of 40–60 indicates a safety profile of sedation depth under general anesthesia. However, the databases used to develop the BIS were based on propofol and did not include electroencephalogram (EEG) data from benzodiazepine [This study has several limitations. First, the remimazolam requirement for SAD can differ according to sex and age [